KALA BIO Inc. (KALA)
NASDAQ: KALA
· Real-Time Price · USD
16.01
0.74 (4.85%)
At close: Sep 11, 2025, 10:35 AM
Company Description
Kala Bio, Inc. is a biopharmaceutical company.
It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases.
The company was founded by Justin Hanes, Robert S.
Langer and Colin R.
Gardner in 2009 and is headquartered in Arlington, MA.
KALA BIO Inc.

Country | United States |
IPO Date | Jul 20, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 38 |
CEO | Todd Bazemore |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts United States | |
Website | https://www.kalarx.com |
Stock Details
Ticker Symbol | KALA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001479419 |
CUSIP Number | 483119103 |
ISIN Number | US4831192020 |
Employer ID | 27-0604595 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Todd Bazemore | Interim Chief Executive Officer, President & Chief Operating Officer |
Mary Reumuth CPA | Chief Financial Officer, Treasurer & Secretary |
Carl Rennie | Executive Director of Account Management |
Darius Kharabi J.D., M.B.A. | Chief Business Officer |
Dr. Francis S. Mah M.D. | Chief Medical Advisor |
Dr. Justin Hanes Ph.D. | Founder & Chair of the Scientific Advisory Board |
Dr. R. Kim Brazzell Ph.D. | Head of R&D and Chief Medical Officer |
Jill S. Steier | Executive Director of Investor Relations & Corporate Communications |
Josiah Craver | Senior Vice President & Corporate Controller |
Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 02, 2025 | 4 | Filing |
Sep 02, 2025 | 8-K | Current Report |
Aug 08, 2025 | 10-Q | Quarterly Report |
Aug 08, 2025 | 8-K | Current Report |
Jul 09, 2025 | 8-K | Current Report |
Jun 26, 2025 | 4 | Filing |
Jun 26, 2025 | 4 | Filing |
Jun 26, 2025 | 4 | Filing |
Jun 26, 2025 | 4 | Filing |
Jun 26, 2025 | 4 | Filing |